Latest filings (excl ownership)
15F-12B
Securities registration termination (foreign)
24 Apr 23
EFFECT
Notice of effectiveness
24 Apr 23
EFFECT
Notice of effectiveness
24 Apr 23
EFFECT
Notice of effectiveness
24 Apr 23
POS AM
Prospectus update (post-effective amendment)
18 Apr 23
POS AM
Prospectus update (post-effective amendment)
18 Apr 23
POS AM
Prospectus update (post-effective amendment)
18 Apr 23
6-K
Current report (foreign)
12 Apr 23
25-NSE
Exchange delisting
12 Apr 23
6-K
High Court of Justice of England and Wales Sanctions Scheme of Arrangement
3 Apr 23
6-K
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
23 Mar 23
6-K
Current report (foreign)
16 Feb 23
6-K
Current report (foreign)
9 Jan 23
6-K
Current report (foreign)
3 Jan 23
6-K
Current report (foreign)
3 Nov 22
6-K
Results of Annual General Meeting
4 Aug 22
6-K
Posting of Annual Report and Notice of AGM
1 Jul 22
6-K
Filsuvez® recently approved by the European Commission for the treatment of EB
24 Jun 22
6-K
European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB
23 Jun 22
6-K
Current report (foreign)
9 Jun 22
6-K
Current report (foreign)
1 Jun 22
EFFECT
Notice of effectiveness
23 May 22
424B4
Prospectus supplement with pricing info
20 May 22
424B4
Prospectus supplement with pricing info
20 May 22
424B4
Prospectus supplement with pricing info
20 May 22
EFFECT
Notice of effectiveness
19 May 22
EFFECT
Notice of effectiveness
19 May 22
CORRESP
Correspondence with SEC
18 May 22
UPLOAD
Letter from SEC
18 May 22
F-3
Shelf registration (foreign)
11 May 22
POS AM
Prospectus update (post-effective amendment)
11 May 22
POS AM
Prospectus update (post-effective amendment)
11 May 22
6-K
Current report (foreign)
11 May 22
424B3
Prospectus supplement
4 May 22
424B3
Prospectus supplement
4 May 22
6-K
Amryt Reports Record Q1 2022 Results
4 May 22
20-F
2021 FY
Annual report (foreign)
29 Apr 22
424B3
Prospectus supplement
31 Mar 22
424B3
Prospectus supplement
31 Mar 22
6-K
Results of General Meeting
31 Mar 22
Latest ownership filings
SC 13G/A
Athyrium Opportunities III Acquisition 2 LP
18 Apr 23
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 23
SC 13G/A
Rubric Capital Management LP
10 Feb 23
SC 13G/A
HIGHBRIDGE CAPITAL MANAGEMENT LLC
10 Feb 23
SC 13G/A
UBS OCONNOR LLC
14 Feb 22
SC 13G
Rubric Capital Management LP
14 Feb 22
SC 13G/A
Stonepine Capital Management, LLC
11 Feb 22
SC 13G/A
HIGHBRIDGE CAPITAL MANAGEMENT LLC
11 Feb 22
SC 13G/A
EdgePoint Investment Group Inc.
11 Feb 22
SC 13G
EdgePoint Investment Group Inc.
5 May 21
SC 13G
UBS OCONNOR LLC
16 Feb 21
SC 13G/A
Stonepine Capital Management, LLC
12 Feb 21
SC 13G
Athyrium Opportunities III Acquisition 2 LP
12 Feb 21
SC 13G
HIGHBRIDGE CAPITAL MANAGEMENT LLC
5 Feb 21
SC 13G
STONEPINE CAPITAL, L.P.
22 Dec 20